The new codes, granted by the American Medical Association (AMA), cover temporary transvenous diaphragm neurostimulation with AeroPace. These temporary codes, which went into effect on July 1, 2026, enable the standardized reporting of procedures and support the development of future reimbursement pathways.
Exton, Pennsylvania-based Lungpacer said the new codes build on the New Technology Add-On Payment (NTAP) granted by the Centers for Medicare & Medicaid Services (CMS) for AeroPace, effective October 1, 2025. The NTAP allows for up to approximately $23,650 in additional reimbursement per case to offset the cost of the technology.
Lungpacer’s latest reimbursement wins highlight another milestone in the clinical adoption of diaphragm neurostimulation for the temporary treatment of intensive care unit (ICU) patients on mechanical ventilation. Critically ill patients on mechanical ventilation often experience rapid diaphragm weakening. This can prolong ventilator dependance and complicate recovery.
AeroPace uses neurostimulation via an electrode-containing cardiovascular catheter and a software-controlled system. It delivers periodic phrenic nerve stimulation through the venous catheter. The system contracts and strengthens the diaphragm in patients on mechanical ventilation.
Lungpacer received FDA premarket approval for its flagship AeroPace system in late 2024. It reported the first commercial procedure in December 2025. The company also has a next-generation version called AeroNova under evaluation in a clinical trial.
Doug Evans, CEO of Lungpacer Medical, said:
“The new Category III CPT codes, together with the NTAP, represent material advancements in our health economics and reimbursement strategy. Hospitals are increasingly focused on technologies that can improve throughput and reduce ICU burden, and these reimbursement milestones support broader access to AeroPace for the patients who need it.”
